Hoemi i ka pilikia o ka na'au e 38%! Ke hoʻololi hou nei ʻo Tirzepatide i ka ʻāina o ka mālama ʻana i ka maʻi cardiovascular

ʻO Tirzepatide, kahi moʻolelo agonist pālua ʻelua (GLP-1/GIP), ua loaʻa ka manaʻo nui i nā makahiki i hala iho nei no kāna kuleana i ka mālama ʻana i ka maʻi diabetes. Eia nō naʻe, ke ulu mālie nei kona hiki i nā maʻi cardiovascular a me renal. Hōʻike nā haʻawina hou e hōʻike ana ka tirzepatide i ka maikaʻi maikaʻi loa i nā poʻe maʻi me ka pau ʻole o ka puʻuwai me ka hapa o ka ejection i mālama ʻia (HFpEF) i hui pū ʻia me ka momona a me ka maʻi maʻi maʻi maʻi (CKD). Ua hōʻike ʻia ka hoʻokolohua lapaʻau SUMMIT he 38% ka hōʻemi ʻana o ka poʻe maʻi e loaʻa ana i ka tirzepatide i ka hopena o ka make ʻana o ka maʻi cardiovascular a i ʻole ke kaumaha o ka naʻau i loko o 52 mau pule, aʻo nā hōʻailona hana renal e like me eGFR i hoʻomaikaʻi nui ʻia. Hāʻawi kēia ʻike i kahi ala lapaʻau hou no nā poʻe maʻi me nā maʻi metabolic paʻakikī.

Ma ke kahua cardiovascular, ʻoi aku ka hana o ka tirzepatide ma mua o ka hoʻoponopono metabolic. Ma ka hoʻoulu ʻana i nā mea loaʻa GLP-1 a me GIP, hoʻemi ia i ka nui o nā adipocytes, a laila e hoʻēmi ana i ke kaomi mechanical o ka ʻiʻo momona ma ka puʻuwai a hoʻomaikaʻi i ka myocardial energy metabolism a me ka hiki anti-ischemic. No ka poʻe maʻi HFpEF, ʻo ka momona a me ka ʻeha mau ka mea kōkua nui, a ʻo ka tirzepatide's dual-receptor activation e hoʻopau pono i ka hoʻokuʻu cytokine inflammatory a hoʻemi i ka myocardial fibrosis, a laila e hoʻopaneʻe i ka deterioration o ka hana cardiac. Hoʻohui ia, hoʻomaikaʻi ia i ka maikaʻi o ke ola i hōʻike ʻia e ka mea maʻi (e like me KCCQ-CSS) a me ka hiki ke hoʻoikaika.

Hōʻike pū ʻo Tirzepatide i nā hopena hoʻohiki i ka pale ʻana i ka renal. Hoʻopili pinepine ʻia ʻo CKD me nā pilikia metabolic a me ka mumū haʻahaʻa. Ke hana nei ka lāʻau lapaʻau ma nā ala ʻelua: hoʻomaikaʻi i ka hemodynamics glomerular e hōʻemi i ka proteinuria, a ke kāohi pono i ke kaʻina o ka fibrosis renal. I ka ho'āʻo SUMMIT, ua hoʻonui nui ka tirzepatide i nā pae eGFR e pili ana i ka cystatin C a hoʻemi i ka albuminuria me ka nānā ʻole inā he CKD ka poʻe maʻi, e hōʻike ana i ka palekana renal piha. Hoʻokumu kēia ʻike i kahi ala hou no ka mālama ʻana i ka nephropathy diabetic a me nā maʻi maʻi maʻi maʻi ʻē aʻe.

ʻOi aku ka maikaʻi o ka waiwai kūʻokoʻa o tirzepatide i nā poʻe maʻi me ka "triad" o ka momona, HFpEF, a me CKD-he pūʻulu me ka maʻamau ʻino. Hoʻomaikaʻi ʻo Tirzepatide i ke ʻano o ke kino (e hōʻemi ana i ka hōʻiliʻili momona a me ka hoʻomaikaʻi ʻana i ka pono metabolic muscle) a hoʻololi i nā ala inflammatory, a laila e hāʻawi ana i ka palekana i hoʻopaʻa ʻia ma nā ʻāpana he nui. Ke hoʻomau nei ka hoʻonui ʻana o nā hōʻailona no ka tirzepatide, ua mākaukau ia e lilo i kumu lāʻau lapaʻau i ka mālama ʻana i nā maʻi metabolic me nā comorbidities.